Latest Therapeutics News

Page 24 of 48
Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy to dose level 2 in its Phase 1/2 trial, showing promising early anti-tumor activity and a strong safety profile in gastrointestinal and neuroendocrine cancers.
Ada Torres
Ada Torres
4 Aug 2025
Cardiex reported strong growth in its Pulse arterial health monitor sales during Q4 FY25, surpassing A$0.7 million for the year and advancing its transition to subscription-based digital health services.
Ada Torres
Ada Torres
31 July 2025
Tryptamine Therapeutics has initiated the first-ever clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with patient dosing set to begin shortly and results expected by year-end.
Ada Torres
Ada Torres
31 July 2025
Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.
Ada Torres
Ada Torres
31 July 2025
Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.
Ada Torres
Ada Torres
31 July 2025
Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.
Ada Torres
Ada Torres
31 July 2025
Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.
Ada Torres
Ada Torres
31 July 2025
Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.
Ada Torres
Ada Torres
31 July 2025
Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.
Ada Torres
Ada Torres
31 July 2025
Imugene Limited reports strong clinical progress with its off-the-shelf CAR T therapy azer-cel achieving a 75% overall response rate in Phase 1b trials, alongside new patents and leadership appointments. The company also secured $22.5 million in fresh funding to advance pivotal trials.
Ada Torres
Ada Torres
31 July 2025
Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.
Ada Torres
Ada Torres
31 July 2025
Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.
Ada Torres
Ada Torres
31 July 2025